(Bloomberg) -- GlaxoSmithKline Plc convinced a U.S.
regulatory panel this week to keep its best-selling diabetes
drug, Avandia, on the market. Now comes the hard part: persuading
doctors to use a medicine linked to heart attacks.
The U.S. Food and Drug Administration committee of advisers
said this week that the diabetes pill should carry new warnings
about cardiovascular risks. Glaxo shares had their biggest gain
in two years yesterday after the advisory panel decided not to
recommend the withdrawal of Avandia, which brought in $3.3
billion in 2006 for the London-based company, Europe's largest
drugmaker.
Read more at Bloomberg Exclusive News
regulatory panel this week to keep its best-selling diabetes
drug, Avandia, on the market. Now comes the hard part: persuading
doctors to use a medicine linked to heart attacks.
The U.S. Food and Drug Administration committee of advisers
said this week that the diabetes pill should carry new warnings
about cardiovascular risks. Glaxo shares had their biggest gain
in two years yesterday after the advisory panel decided not to
recommend the withdrawal of Avandia, which brought in $3.3
billion in 2006 for the London-based company, Europe's largest
drugmaker.
Read more at Bloomberg Exclusive News
No comments:
Post a Comment